MOHN KG, Zhou F, Brokstad KA, Sridhar S, et al. Live attenuated influenza vaccination boosts durable cross-reactive and protection-associated T-cells in children. J Infect Dis. 2017 Mar 27. doi: 10.1093
Background:
Live attenuated influenza vaccines (LAIV) stimulate a multifaceted immune response including cellular immunity, which may provide protection against newly emerging strains. This study shows proof of concept that LAIV boosts pre-existing, cross-reactive T-cells in children to genetically diverse influenza A strains to which the children had not been exposed.
Methods:
We studied the long-term cross-reactive T-cell response in 14 trivalent LAIV vaccinated children using the fluorescent immunospot assay (FluroSpot) with heterologous H1N1 and H3N2 influenza A viruses and CD8 peptides from the internal proteins (M1, NP, PB1). Serum antibody responses were determined by the Hemagglutination Inhibition (HI). Blood samples were collected before vaccination and up to one year post-vaccination.
Results:
Pre-existing cross-reactive T-cells to genetically diverse influenza A strains were found in the majority of the children, which were further boosted in 50% of the children after LAIV. Further analyses of these T-cells showed significant increases in CD8+ T-cells, mainly dominated by NP specific responses. After LAIV, the youngest children showed the highest increase in T-cell responses.
Conclusion:
LAIV boosts durable, cross-reactive T-cell responses in children and may have a clinically protective effect at the population level. LAIV may be a first step towards the desired universal influenza vaccine.
Live attenuated influenza vaccines (LAIV) stimulate a multifaceted immune response including cellular immunity, which may provide protection against newly emerging strains. This study shows proof of concept that LAIV boosts pre-existing, cross-reactive T-cells in children to genetically diverse influenza A strains to which the children had not been exposed.
Methods:
We studied the long-term cross-reactive T-cell response in 14 trivalent LAIV vaccinated children using the fluorescent immunospot assay (FluroSpot) with heterologous H1N1 and H3N2 influenza A viruses and CD8 peptides from the internal proteins (M1, NP, PB1). Serum antibody responses were determined by the Hemagglutination Inhibition (HI). Blood samples were collected before vaccination and up to one year post-vaccination.
Results:
Pre-existing cross-reactive T-cells to genetically diverse influenza A strains were found in the majority of the children, which were further boosted in 50% of the children after LAIV. Further analyses of these T-cells showed significant increases in CD8+ T-cells, mainly dominated by NP specific responses. After LAIV, the youngest children showed the highest increase in T-cell responses.
Conclusion:
LAIV boosts durable, cross-reactive T-cell responses in children and may have a clinically protective effect at the population level. LAIV may be a first step towards the desired universal influenza vaccine.
See Also:
Latest articles in those days:
- Latest developments in early diagnosis and specific treatment of severe influenza infection 5 hours ago
- Factors affecting highly pathogenic avian influenza vaccination practices at poultry farms in Tra Vinh, Vietnam 5 hours ago
- Establishment of Swine Primary Nasal, Tracheal, and Bronchial Epithelial Cell Culture Models for the Study of Influenza Virus Infection 1 days ago
- Highly pathogenic avian influenza H5N1 virus infections in pinnipeds and seabirds in Uruguay: implications for bird-mammal transmission in South America 1 days ago
- Development and evaluation of a multiplex real-time RT-PCR assay for simultaneous detection of H5, H7, and H9 subtype avian influenza viruses 2 days ago
[Go Top] [Close Window]